340 related articles for article (PubMed ID: 34654836)
1. siRNA delivery using intelligent chitosan-capped mesoporous silica nanoparticles for overcoming multidrug resistance in malignant carcinoma cells.
Heidari R; Khosravian P; Mirzaei SA; Elahian F
Sci Rep; 2021 Oct; 11(1):20531. PubMed ID: 34654836
[TBL] [Abstract][Full Text] [Related]
2. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
3. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
4. Intracellular cleavable poly(2-dimethylaminoethyl methacrylate) functionalized mesoporous silica nanoparticles for efficient siRNA delivery in vitro and in vivo.
Lin D; Cheng Q; Jiang Q; Huang Y; Yang Z; Han S; Zhao Y; Guo S; Liang Z; Dong A
Nanoscale; 2013 May; 5(10):4291-301. PubMed ID: 23552843
[TBL] [Abstract][Full Text] [Related]
5. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
Ma X; Zhao Y; Ng KW; Zhao Y
Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
[TBL] [Abstract][Full Text] [Related]
6. Fabrication of Chitosan-coated Mesoporous Silica Nanoparticles Bearing Rosuvastatin as a Drug Delivery System.
Ghahfarokhi MR; Dini G; Movahedi B
Curr Drug Deliv; 2022; 19(1):64-73. PubMed ID: 34151762
[TBL] [Abstract][Full Text] [Related]
7. Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy.
Hanafi-Bojd MY; Jaafari MR; Ramezanian N; Abnous K; Malaekeh-Nikouei B
Curr Drug Deliv; 2016; 13(7):1176-1182. PubMed ID: 26718488
[TBL] [Abstract][Full Text] [Related]
8. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
9. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
10. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
11. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
12. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
13. Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy.
Rezaei Harandi Z; Heidari R; Reiisi S
IEEE Trans Nanobioscience; 2023 Oct; 22(4):872-880. PubMed ID: 37022888
[TBL] [Abstract][Full Text] [Related]
14. Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
Shi XL; Li Y; Zhao LM; Su LW; Ding G
Colloids Surf B Biointerfaces; 2019 Jan; 173():599-606. PubMed ID: 30352381
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
[TBL] [Abstract][Full Text] [Related]
16. A mesoporous silica nanoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy.
Li X; Chen Y; Wang M; Ma Y; Xia W; Gu H
Biomaterials; 2013 Jan; 34(4):1391-401. PubMed ID: 23164421
[TBL] [Abstract][Full Text] [Related]
17.
Mohebian Z; Babazadeh M; Zarghami N
Adv Pharm Bull; 2023 Mar; 13(2):317-327. PubMed ID: 37342377
[No Abstract] [Full Text] [Related]
18. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment.
Shakeran Z; Keyhanfar M; Varshosaz J; Sutherland DS
Mater Sci Eng C Mater Biol Appl; 2021 Jan; 118():111526. PubMed ID: 33255079
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-glucuronic acid conjugate coated mesoporous silica nanoparticles: A smart pH-responsive and receptor-targeted system for colorectal cancer therapy.
Narayan R; Gadag S; Cheruku SP; Raichur AM; Day CM; Garg S; Manandhar S; Pai KSR; Suresh A; Mehta CH; Nayak Y; Kumar N; Nayak UY
Carbohydr Polym; 2021 Jun; 261():117893. PubMed ID: 33766378
[TBL] [Abstract][Full Text] [Related]
20. [GGI as a gene carrier delivering MDR1 siRNA to A549/DDP cells for reversal of multidrug resistance].
Wang ZR; Bai F; Zhang XY; Wu JM; Guo L; Li Z; Feng M
Yao Xue Xue Bao; 2017 Feb; 52(2):309-17. PubMed ID: 29979530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
